The U.S. FDA late Friday approved BridgeBio Pharma’s (NASDAQ:BBIO) lead asset Attruby for the rare heart disorder ...

We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, we are going to take a look ...

Equities researchers at Cantor Fitzgerald decreased their FY2024 earnings estimates for BridgeBio Pharma in a report released ...

On Monday, BridgeBio Pharma, Inc. (NASDAQ:BBIO) presented initial outcomes from the ATTRibute-CM open-label extension (OLE) ...

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have been assigned an average recommendation of “Moderate ...

In a report released today, Greg Harrison from Scotiabank maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report), with a price ...

BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price upped by Scotiabank from $44.00 to $45.00 in a research note published on Friday,Benzinga reports. The brokerage currently has a ...

One thing we could say about the analysts on BridgeBio Pharma, Inc. ( NASDAQ:BBIO) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the ...

BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $1.03. This compares to loss of $1.08 per share a year ago. These figures ...

Equities research analysts at Leerink Partnrs lowered their FY2024 earnings per share (EPS) estimates for shares of BridgeBio ...

PALO ALTO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a new ...

However, on the same day, Oppenheimer maintained a Hold rating on BridgeBio Pharma (NASDAQ: BBIO). BBIO market cap is currently $4.63B and has a P/E ratio of -10.21. Based on the recent corporate ...